Key Documents

View All Documentation

T4827

Trandolapril

Name: Trandolapril
Brand: SIGMA

≥98% (HPLC), white, powder

Synonym(s):

(2S,3aR,7aS)-1-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-1H-indole-2-carboxylic acid, Mavik

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₂₄H₃₄N₂O₅

CAS Number:

87679-37-6

Molecular Weight:

430.54

NACRES:

NA.77

PubChem Substance ID:

329826801

UNSPSC Code:

12352200

MDL number:

MFCD00865776

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

100

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white

solubility

DMSO: ≥20 mg/mL

originator

Abbott

SMILES string

CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N2C3CCCCC3C[C@H]2C(O)=O

InChI

1S/C24H34N2O5/c1-3-31-24(30)19(14-13-17-9-5-4-6-10-17)25-16(2)22(27)26-20-12-8-7-11-18(20)15-21(26)23(28)29/h4-6,9-10,16,18-21,25H,3,7-8,11-15H2,1-2H3,(H,28,29)/t16-,18+,19-,20-,21-/m0/s1

InChI key

VXFJYXUZANRPDJ-WTNASJBWSA-N

Gene Information

human ... ACE(1636)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Bioactive Small Molecule Inhibitors

Application

Trandolapril has been used as an angiotensin-converting enzyme (ACE) inhibitor to study its effects on responsiveness of human retinal endothelial cells (HRECs) to vascular endothelial growth factor (VEGF).

Biochem/physiol Actions

Studies have reported that trandolapril inhibits atherosclerosis¹ and decreases the occurrence of atrial fibrillation².

Trandolapril is an ACE inhibitor.

Trandolapril is an ACE inhibitor. Trandolapril differs from other ACE inhibitors in that it has a longer biological half-life and a high degree of lipophilicity.

Features and Benefits

This compound was developed by Abbott. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Preparation Note

Trandolapril is soluble in DMSO at a concentration that is greater than or equal to 20 mg/ml.

pictograms

GHS08

signalword

Danger

hcodes

H360D

pcodes

P201 - P202 - P280 - P308 + P313 - P405 - P501

Hazard Classifications

Repr. 1B

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

0000013524

0000150600

0000133984

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction.

O D Pedersen et al.

Circulation, 100(4), 376-380 (1999-07-27)

Studies have suggested that ACE inhibitors have an antiarrhythmic effect on ventricular arrhythmias. Whether they have an effect on atrial fibrillation is unknown. We investigated the effect of ACE inhibition with trandolapril on the incidence of atrial fibrillation in patients

Effects of combined endothelin A receptor and renin-angiotensin system blockade on the course of end-organ damage in 5/6 nephrectomized Ren-2 hypertensive rats.

Ivana Vaněčková et al.

Kidney & blood pressure research, 35(5), 382-392 (2012-04-11)

Our previous studies in rats with ablation nephrectomy have shown similar cardiorenal protective effects of renin-angiotensin system (RAS)-dependent treatment (combination of angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker) and RAS-independent treatment (combination of α- and β-adrenoreceptor antagonist and diuretics).

Impact of trandolapril therapy and its combination with a calcium channel blocker on plasma adiponectin levels in patients with type 2 diabetes and hypertension.

Alberto F Rubio-Guerra et al.

Therapeutic advances in cardiovascular disease, 5(4), 193-197 (2011-07-09)

Adiponectin is secreted from adipose tissue and exhibits a protective effect against cardiovascular disease; plasma adiponectin concentrations are decreased in type 2 diabetic and in hypertensive patients. The aim of this study was to compare the effect of trandolapril (T)

Plasma sodium and mortality risk in patients with myocardial infarction and a low LVEF.

Morten Schou et al.

European journal of clinical investigation, 41(11), 1237-1244 (2011-05-11)

Hyponatremia is a known prognostic factor for mortality in patients with heart failure but has not been extensively studied in patients with myocardial infarction (MI). This study was, therefore, designed to evaluate whether plasma sodium and hyponatremia (< 135 mM)

Comparing marginal structural models to standard methods for estimating treatment effects of antihypertensive combination therapy.

Tobias Gerhard et al.

BMC medical research methodology, 12, 119-119 (2012-08-08)

Due to time-dependent confounding by blood pressure and differential loss to follow-up, it is difficult to estimate the effectiveness of aggressive versus conventional antihypertensive combination therapies in non-randomized comparisons. We utilized data from 22,576 hypertensive coronary artery disease patients, prospectively

View All Related Papers

Global Trade Item Number

SKU	GTIN
T4827-50MG	04061832949949
T4827-10MG	04061832949932

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service